✦ LIBER ✦

PCN145 Treatment Patterns and Outcomes Among Patients With Unresectable Stage III or Stage IV Melanoma in Mexico

✍ Scribed by Silva, A.; Lázaro-León, M.; de la peña, R.; Frausto, P.; Vargas-Valencia, J.J.; Gómez-Roel, X.; Juarez-Garcia, A.; Donato, B.M.K.; Martinez-Rivera, G.; Hernández-Rivera, G.

Book ID: 122203994
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 59 KB
Volume: 15
Category: Article
ISSN: 1098-3015
DOI: 10.1016/j.jval.2012.03.1262

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN113 TREATMENT PATTERNS AND OUTCOMES I

PCN113 TREATMENT PATTERNS AND OUTCOMES IN THE FRENCH COHORT OF PATIENTS WITH UNRESECTABLE STAGE III OR STAGE IV MELANOMA (MELODY STUDY): A RETROSPECTIVE LONGITUDINAL SURVEY

✍ C Bédane; MT Leccia; B Sassolas; S Mansard; B Guillot; L Mortier; C Robert; P Sa 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

Treatment patterns and outcomes among pa

Treatment patterns and outcomes among patients diagnosed with unresectable stage III or IV melanoma in Europe: A retrospective, longitudinal survey (MELODY study)

✍ C. Lebbe; P. Lorigan; P. Ascierto; A. Testori; C. Bédane; M. Middleton; M. van B 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 549 KB

PCN45 Epidemiology, Treatment Patterns a

PCN45 Epidemiology, Treatment Patterns and Costs in Patients With Stage III/IV Melanoma

✍ Lugowska, I.; Szkutecka-Debek, M.; Sozanska-Solak, A.; Ziobro, M.; Wysocki, P.; 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

PCN2 A Retrospective Longitudinal Study

PCN2 A Retrospective Longitudinal Study of Treatment Patterns and Outcomes Among Patients with Unresectable Stage IIIc/IV Melanoma in Canada (Melody)

✍ Osenenko, K.; Szabo, S.M.; Schultz, M.; Mihalcioiu, C.; Lane, S.; Levy, A.R. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB

Health related quality of life outcomes

✍ Revicki, Dennis A; van den Eertwegh, Alfons JM; Lorigan, Paul; Lebbe, Celeste; L 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 273 KB

Randomized phase 2/3 trial of CpG oligod

Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma

✍ Jeffrey S. Weber; Hassan Zarour; Bruce Redman; Uwe Trefzer; Steven O'Day; Alfons 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 242 KB

## Abstract ## BACKGROUND: The primary objective of this phase 2 study was to assess the objective response rate (complete response [CR] + partial responses [PR]), by Response Evaluation Criteria in Solid Tumors, of PF‐3512676, a CpG oligodeoxynucleotide, alone in 2 doses or in combination with da